Claims for Patent: 8,921,367

Summary for Patent: 8,921,367

Title:	Use of AMG 900 for the treatment of cancer
Abstract:	The present invention relates to methods of using AMG 900, a small molecule pan aurora kinase inhibitor, for the treatment of cancer, including solid tumors, hematologically derived tumors and the like. The invention further provides pharmaceutical compositions, dosage ranges and treatment regimens for administering AMG 900 to treat cancer.
Inventor(s):	Friberg; Gregory (Westlake Village, CA), Payton; Marc (Newbury Park, CA)
Assignee:	Amgen Inc. (Thousand Oaks, CA)
Application Number:	13/906,231
Patent Claims:	1. A method of treating cancer in a human comprising administering to the human a dosage regimen comprising administering AMG 900, or a pharmaceutically acceptable salt thereof, orally to the human for 4, 5, 6 or 7 consecutive days, a once daily dose ranging from about 1 mg to about 80 mg. 2. The method of claim 1 wherein AMG 900, or a pharmaceutically acceptable salt thereof, is administered in a once daily dose ranging from about 5 mg to about 45 mg. 3. The method of claim 1 wherein AMG 900, or a pharmaceutically acceptable salt thereof, is administered in a once daily dose ranging from about 16 mg to about 35 mg. 4. The method of claim 1 wherein AMG 900, or a pharmaceutically acceptable salt thereof, is administered in a once daily dose ranging from about 20 mg to about 25 mg. 5. The method of claim 1 wherein AMG 900, or a pharmaceutically acceptable salt thereof, is administered in a once daily dose of about 24 mg. 6. The method of claim 1 wherein AMG 900 is administered in a once daily dose ranging from about 40 mg to about 80 mg. 7. The method of claim 1 wherein the dosage regimen comprises orally administering AMG 900, or a pharmaceutically acceptable salt thereof, to the human for 4 consecutive days. 8. The method of claim 1 wherein the dosage regimen comprises orally administering AMG 900, or a pharmaceutically acceptable salt thereof, to the human for 7 consecutive days. 9. The method of claim 1 wherein the dosage regimen comprises orally administering AMG 900, or a pharmaceutically acceptable salt thereof, to the human for 4, 5, 6 or 7 consecutive days followed immediately by non-treatment of AMG 900, or a pharmaceutically acceptable salt thereof, for a period ranging from 6 to 20 consecutive days. 10. The method of claim 1 wherein the dosage regimen comprises orally administering AMG 900, or a pharmaceutically acceptable salt thereof, to the human for 4 or 7 consecutive days followed immediately by non-treatment of AMG 900, or a pharmaceutically acceptable salt thereof, for a period ranging from 6 or 15 consecutive days. 11. The method of claim 1 wherein the dosage regimen further comprises administering AMG 900, or a pharmaceutically acceptable salt thereof, in combination with GCSF. 12. The method of claim 11 wherein the GCSF is administered in an amount ranging from about 5 mcg/kg to about 200 mcg/kg by weight of the human. 13. The method of claim 11 wherein AMG 900, or a pharmaceutically acceptable salt thereof, is administered in a once daily dose ranging from about 20 mg to about 40 mg in combination with GCSF administered in an amount ranging from about 5 mcg/kg to about 200 mcg/kg by weight of the human. 14. The method of claim 1 wherein the dosage regimen further comprises fasting the human for at least one hour immediately prior to administering AMG 900, or a pharmaceutically acceptable salt thereof, and for at least another 2 hours immediately after administering AMG 900, or a pharmaceutically acceptable salt thereof. 15. The method of claim 1 wherein the cancer is one or more of (a) a solid or hematologically derived tumor selected from (a) cancer of the bladder, breast, colon, kidney, liver, lung, small cell lung cancer, esophagus, gall-bladder, ovary, endometrium, pancreas, stomach, uterus, cervix, thyroid, brain, prostate and skin, (b) a hematopoietic tumor of lymphoid lineage selected from leukemia, acute lymphocitic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and Burkett's lymphoma, (c) a hematopoietic tumor of myeloid lineage selected from acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukemia (d) a tumor of mesenchymal origin selected from fibrosarcoma and rhabdomyosarcoma, (e) a tumor of the central and peripheral nervous system selected from astrocytoma, neuroblastoma, glioma and schwannoma, and (f) a melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer or Kaposi's sarcoma. 16. The method of claim 1 wherein the cancer is one or more of a solid tumor selected from cancer of the bladder, breast, colon, kidney, liver, lung, non-small cell lung, head and neck, esophageal, gastric, ovary, endometrium, pancreas, stomach, uterus, cervix, thyroid, brain and prostate or a lymphoma or leukemia, or a combination thereof. 17. The method of claim 1 wherein the cancer is a solid cancer tumor of the prostate, ovary, endometrium, breast, bladder, colon, kidney, liver, lung, esophagus, pancreas, stomach, uterus, cervix, thyroid, brain or skin, or a combination thereof. 18. The method of claim 1 wherein the cancer is (a) a hematopoietic tumor of lymphoid lineage selected from leukemia, acute lymphocitic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and Burkett's lymphoma or (b) a hematopoietic tumor of myeloid lineage selected from acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukemia, or a combination thereof. 19. The method of claim 1 wherein the cancer is a hematopoietic tumor of myeloid lineage selected from acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukemia, or a combination thereof. 20. The method of claim 1 wherein the cancer is selected from the group consisting of prostate cancer, neuroendocrine cancer, ovarian cancer, endometrial cancer, breast cancer, uterine cancer and cervical cancer, or a combination thereof. 21. The method of claim 1 wherein the dosage regimen comprises administering AMG 900, or a pharmaceutically acceptable salt thereof, in combination with a second anti-cancer agent. 22. The method of claim 21 wherein the second anti-cancer agent is methotrexate; tamoxifen; fluorouracil; 5-fluorouracil; hydroxyurea; mercaptopurine; cisplatin; carboplatin; daunorubicin; doxorubicin; etoposide; vinblastine; vincristine; paclitaxel; thioguanine; idarubicin; dactinomycin; imatinib; gemcitabine; altretamine; asparaginase; bleomycin; capecitabine; carmustine; cladibrine; cyclophosphamine; cytarabine; decarazine; docetaxel; idarubicin; ifosfamide; irinotecan; fludarabine; mitosmycin; mitoxane; mitoxantrone; topotecan; vinorelbine; adriamycin; mithram; imiquimod; alemtuzmab; exemestane; bevacizumab; cetuximab; azacitidine; clofarabine; decitabine; desatinib; dexrazoxane; docetaxel; epirubicin; oxaliplatin; erlotinib; raloxifene; fulvestrant; letrozole; gefitinib; gemtuzumab; trastuzumab; gefitinib; ixabepilone; lapatinib; lenalidomide; aminolevulinic acid; temozolomide; nelarabine; sorafenib; nilotinib; pegaspargase; pemetrexed; rituximab; dasatinib; thalidomide; bexarotene; temsirolimus; bortezomib; vorinostat; capecitabine; zoledronic acid; anastrozole; sunitinib; aprepitant or nelarabine, or a combination thereof. 23. The method of claim 1 wherein the dosage regimen comprises fasting the human for one hour immediately prior to and for two hours immediately after administering the once daily dose of AMG 900, or a pharmaceutically acceptable salt thereof. 24. The method of claim 9 wherein the cancer is selected from the group consisting of prostate cancer, neuroendocrine cancer, ovarian cancer, endometrial cancer, breast cancer, uterine cancer and cervical cancer, or a combination thereof. 25. The method of claim 24 wherein the cancer is ovarian cancer. 26. The method of claim 24 wherein the cancer is breast cancer. 27. The method of claim 24 wherein the cancer is prostate cancer. 28. The method of claim 9 wherein the dosage regimen comprises orally administering AMG 900, or a pharmaceutically acceptable salt thereof, to the human once daily for 4 consecutive days followed immediately by non-treatment of the AMG 900 for a period of 10 consecutive days. 29. The method of claim 28 wherein the once daily dose of AMG 900 or a pharmaceutically acceptable salt thereof, is an amount ranging from about 16 mg to about 40 mg. 30. The method of claim 9 wherein the dosage regimen comprises orally administering AMG 900, or a pharmaceutically acceptable salt thereof, to the human once daily for 7 consecutive days followed immediately by non-treatment of the AMG 900 for a period of 7 consecutive days. 31. The method of claim 30 wherein the once daily dose of AMG 900 or a pharmaceutically acceptable salt thereof, is an amount ranging from about 10 mg to about 80 mg.

Details for Patent 8,921,367

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2039-02-26
Servier Pharmaceuticals Llc	ONCASPAR	pegaspargase	Injection	103411	02/01/1994		2039-02-26
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2039-02-26
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2039-02-26
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2039-02-26
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2039-02-26
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2039-02-26